Search

Your search keyword '"Waldner‐combernoux, A"' showing total 40 results
Start Over Author "Waldner‐combernoux, A"
40 results on '"Waldner‐combernoux, A"'

2. Les auteurs

Author

Aubin-Auger, Isabelle, primary, Barais, Marie, additional, Bardet, Jean-Didier, additional, Bayen, Marc, additional, Bègue, Cyril, additional, Benedini, Élise, additional, Binder, Philippe, additional, Blœdé, François, additional, Bouchez, Tiphanie, additional, Bourgueil, Yann, additional, Boussageon, Rémy, additional, Canévet, Jean-Paul, additional, Carbonnel, François, additional, Casanova, Ludovic, additional, Chambe, Juliette, additional, Chamboredon, Benoît, additional, Chanelière, Marc, additional, Chapron, Anthony, additional, Charuel, Élodie, additional, de Chefdebien, Marine, additional, Clément, Renaud, additional, Clerc, Pascal, additional, Coindard, Guillaume, additional, Compagnon, Laurence, additional, Cordonnier, Pauline, additional, Darmon, David, additional, Devillers, Louise, additional, Dibao-Dina, Clarisse, additional, Ducloyer, Mathilde, additional, Duhoux, Bérengère, additional, Dupouy, Julie, additional, Durrieu, Florence, additional, Erpeldinger, Sylvie, additional, Escourrou, Émile, additional, Ferrat, Émilie, additional, Fiquet, Laure, additional, Flora, Luigi, additional, Flori, Marie, additional, François, Mathilde, additional, Frappé, Paul, additional, Freyens, Anne, additional, Gaboreau, Yoann, additional, Ghasarossian, Christian, additional, de La Londe, Julie Gilles, additional, Girard, Pauline, additional, Gocko, Xavier, additional, Haller, Dagmar M., additional, Huas, Caroline, additional, Imbert, Patrick, additional, Jami, Alain, additional, Jeanmougin, Pauline, additional, Jego-Sablier, Maeva, additional, Joseph, Jean-Philippe, additional, Jouannin, Adeline, additional, Kapassi, Amar, additional, Kermiche, François, additional, Kinouani, Shérazade, additional, Khouani, Jérémy, additional, Lamort-Bouché, Marion, additional, Laporte, Catherine, additional, Lebeau, Jean-Pierre, additional, Le Breton, Julien, additional, Letrilliart, Laurent, additional, Liard, Roxane, additional, Maynié-François, Christine, additional, Mazalovic, Katia, additional, Mercier, Alain, additional, Meury Abraham, Pierrette, additional, Mignot, Stéphanie, additional, Million, Élodie, additional, Mitilian, Eva, additional, Monney, Yhan, additional, Moreau, Alain, additional, Moussaoui, Sohela, additional, Paradis, Sabrina, additional, Paumier, Françoise, additional, Perdrix, Corinne, additional, Pouchain, Denis, additional, Ramond-Roquin, Aline, additional, Rat, Cédric, additional, Renard, Vincent, additional, Rossignol, Louise, additional, Bugat, Marie-Eve Rougé, additional, Rousseau, Anne, additional, Rousseau, Rosalie, additional, Ruelle, Yannick, additional, Salmon, Emeline, additional, Sanchez, Delphine, additional, Schuers, Matthieu, additional, Sidorkiewicz, Stéphanie, additional, Tudrej, Benoit, additional, Vandendriessche, Juliette, additional, Vartanian, Cyrille, additional, Virot, Grégoire, additional, Vorilhon, Philippe, additional, Waldner-Combernoux, Anne, additional, and Zabawa, Claire, additional

Published
2022
Full Text
View/download PDF

4. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

Author

Marcellin, Fabienne, Di Beo, Vincent, Esterle, Laure, Abgrall, Sophie, Pialoux, Gilles, Barré, Tangui, Wittkop, Linda, Salmon‐ceron, Dominique, Sogni, Philippe, Carrieri, Patrizia, Roustant, F, Platterier, P, Kmiec, I, Traore, L, Lepuil, S, Parlier, S, Sicart‐payssan, V, Bedel, E, Anriamiandrisoa, S, Pomes, C, Mole, M, Bolliot, C, Catalan, P, Mebarki, M, Adda‐lievin, A, Thilbaut, P, Ousidhoum, Y, Makhoukhi, F.Z, Braik, O, Bayoud, R, Gatey, C, Pietri, M.P, Le Baut, V, Ben Rayana, R, Bornarel, D, Chesnel, C, Beniken, D, Pauchard, M, Akel, S, Lions, C, Ivanova, A, Ritleg, A‐s, Debreux, C, Chalal, L, Zelie, J, Hue, H, Soria, A, Cavellec, M, Breau, S, Joulie, A, Fisher, P, Gohier, S, Croisier‐bertin, D, Ogoudjobi, S, Brochier, C, Thoirain‐galvan, V, Le Cam, M, Chalouni, M, Conte, V, Dequae‐merchadou, L, Desvallees, M, Gilbert, C, Gillet, S, Knight, R, Lemboub, T, Michel, L, Mora, M, Protopopescu, C, Roux, P, Tezkratt, S, Ramier, C, Sow, A, Bureau, M, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Spire, B, Valantin, V., Chas, J, Zaegel‐faucher, O, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐see, A, Bouchaud, O, Gervais, A, Lascoux‐combe, C, Goujard, C, Lacombe, K, Duvivier, C, Neau, D, Morlat, P, Bani‐sadr, F, Meyer, L, Boufassa, F, Autran, B, Roque, A.M, Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Rey, D, Peytavin, G, Petrov‐sanchez, V, Levier, A, Usubillaga, R., Terris, B, Tremeaux, P, Katlama, C, Stitou, H, Cacoub, P, Nafissa, S, Benhamou, Y, Charlotte, F, Fourati, S, Poizot‐martin, I, Zaegel, O, Laroche, H, Tamalet, C, Callard, P, Bendjaballah, F, Amiel, C, Le Pendeven, C, Marchou, B, Alric, L, Metivier, S, Selves, J, Larroquette, F, Rio, V, Haudebourg, J, Saint‐paul, M.C, de Monte, A, Giordanengo, V, Partouche, C, Martin, A, Ziol, M, Baazia, Y, Iwaka‐bande, V, Gerber, A, Uzan, M, Garipuy, D, Ferro‐collados, M.J, Nicot, F, Yazdanpanah, Y, Adle‐biassette, H, Alexandre, G, Molina, J.M, Bertheau, P, Chaix, M.L, Delaugerre, C, Maylin, S, Bottero, J, Krause, J, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Vittecocq, D, Quertainmont, Y, Teicher, E, Pallier, C, Lortholary, O, Rouzaud, C, Lourenco, J, Touam, F, Louisin, C, Avettand‐fenoel, V, Gardiennet, E, Mélard, A, Ochoa, A, Blanchard, E, Castet‐lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐buzy, L, Desclaux, A, Bioulac‐sage, P, Reigadas, S, Lacoste, D, Bonnet, F, Bernard, N, Hessamfar, M, Paccalin, J.F, Martell, C, Pertusa, M.C, Vandenhende, M, Mercié, P, Pistone, T, Receveur, M.C, Méchain, M, Duffau, P, Rivoisy, C, Faure, I, Caldato, S, Bellecave, P, Tumiotto, C, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Majerholc, C, Brollo, M, Farfour, E, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Favier, M, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Raffi, F, Allavena, C, Reliquet, V, Boutoille, D, Biron, C, Lefebvre, M, Hall, N, Bouchez, S, Rodallec, A, Le Guen, L, Hemon, C, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Valour, F, Augustin‐normand, C, Scholtes, C, Le‐thi, T.T, Chavanet, P, Duong van Huyen, M, Buisson, M, Waldner‐combernoux, A, Mahy, S, Salmon Rousseau, A, Martins, C, Galim, S, Lambert, D, Nguyen, Y, Berger, J.L, Hentzien, M, Brodard, V, Partisani, M, Batard, M.L, Cheneau, C, Priester, M, Bernard‐henry, C, de Mautort, E, Fischer, P, Gantner, P, Fafi‐kremer, S, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Team MORPH3EUS (INSERM U1219 - UB - ISPED), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Bordeaux [Bordeaux], Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), ANRS CO13 HEPAVIH Study Group: F Roustant, P Platterier, I Kmiec, L Traore, S Lepuil, S Parlier, V Sicart-Payssan, E Bedel, S Anriamiandrisoa, C Pomes, M Mole, C Bolliot, P Catalan, M Mebarki, A Adda-Lievin, P Thilbaut, Y Ousidhoum, F Z Makhoukhi, O Braik, R Bayoud, C Gatey, M P Pietri, V Le Baut, R Ben Rayana, D Bornarel, C Chesnel, D Beniken, M Pauchard, S Akel, C Lions, A Ivanova, A-S Ritleg, C Debreux, L Chalal, J Zelie, H Hue, A Soria, M Cavellec, S Breau, A Joulie, P Fisher, S Gohier, D Croisier-Bertin, S Ogoudjobi, C Brochier, V Thoirain-Galvan, M Le Cam, M Chalouni, V Conte, L Dequae-Merchadou, M Desvallees, C Gilbert, S Gillet, R Knight, T Lemboub, L Michel, M Mora, C Protopopescu, P Roux, S Tezkratt, C Ramier, A Sow, M Bureau, P Trimoulet, J Izopet, L Serfaty, V Paradis, B Spire, Valantin, J Chas, O Zaegel-Faucher, K Barange, A Naqvi, E Rosenthal, A Bicart-See, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Neau, P Morlat, F Bani-Sadr, L Meyer, F Boufassa, B Autran, A M Roque, C Solas, H Fontaine, D Costagliola, L Piroth, A Simon, D Zucman, F Boué, P Miailhes, E Billaud, H Aumaître, D Rey, G Peytavin, V Petrov-Sanchez, A Levier, R Usubillaga, B Terris, P Tremeaux, C Katlama, H Stitou, P Cacoub, S Nafissa, Y Benhamou, F Charlotte, S Fourati, I Poizot-Martin, O Zaegel, H Laroche, C Tamalet, P Callard, F Bendjaballah, C Amiel, C Le Pendeven, B Marchou, L Alric, S Metivier, J Selves, F Larroquette, V Rio, J Haudebourg, M C Saint-Paul, A De Monte, V Giordanengo, C Partouche, A Martin, M Ziol, Y Baazia, V Iwaka-Bande, A Gerber, M Uzan, D Garipuy, M J Ferro-Collados, J Selves, F Nicot, Y Yazdanpanah, H Adle-Biassette, G Alexandre, J M Molina, P Bertheau, M L Chaix, C Delaugerre, S Maylin, J Bottero, J Krause, P M Girard, D Wendum, P Cervera, J Adam, C Viala, D Vittecocq, Y Quertainmont, E Teicher, C Pallier, O Lortholary, C Rouzaud, J Lourenco, F Touam, C Louisin, V Avettand-Fenoel, E Gardiennet, A Mélard, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy, A Desclaux, P Bioulac-Sage, S Reigadas, D Lacoste, F Bonnet, N Bernard, M Hessamfar, J F Paccalin, C Martell, M C Pertusa, M Vandenhende, P Mercié, D Malvy, T Pistone, M C Receveur, M Méchain, P Duffau, C Rivoisy, I Faure, S Caldato, P Bioulac-Sage, S Reigadas, P Bellecave, C Tumiotto, J L Pellegrin, J F Viallard, E Lazzaro, C Greib, P Bioulac-Sage, S Reigadas, C Majerholc, M Brollo, E Farfour, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez, M Favier, C Deback, Y Lévy, S Dominguez, J D Lelièvre, A S Lascaux, G Melica, F Raffi, C Allavena, V Reliquet, D Boutoille, C Biron, M Lefebvre, N Hall, S Bouchez, A Rodallec, L Le Guen, C Hemon, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri, F Valour, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, C Augustin-Normand, C Scholtes, T T Le-Thi, P Chavanet, M Duong Van Huyen, M Buisson, A Waldner-Combernoux, S Mahy, A Salmon Rousseau, C Martins, S Galim, D Lambert, Y Nguyen, J L Berger, M Hentzien, V Brodard, M Partisani, M L Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P Fischer, P Gantner, S Fafi-Kremer, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), and Malbec, Odile

Subjects
0303 health sciences, Hepatology, business.industry, [SDV]Life Sciences [q-bio], Human immunodeficiency virus (HIV), MEDLINE, Physical activity, medicine.disease_cause, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Virology, Medicine, 030211 gastroenterology & hepatology, business, Eating behaviour, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, Clinical psychology
Abstract

International audience; No abstract available

Published
2021

5. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

Author

Salmon, D., Usubillaga, R., Sogni, P., Terris, B., Tremeaux, P., Katlama, C., Valantin, M.A., Stitou, H., Simon, A., Cacoub, P., Nafissa, S., Benhamou, Y., Charlotte, F., Fourati, Virologie: S., Poizot-Martin, I., Zaegel, O., Laroche, H., Tamalet, C., Pialoux, G., Chas, J., Callard, P., Bendjaballah, F., Amiel, C., Le Pendeven, C., Marchou, B., Alric, L., Barange, K., Metivier, S., Selves, J., Larroquette, F., Rosenthal, E., Infectiologie, Naqvi, A., Rio, V., Haudebourg, J., Saint-Paul, M.C., Monte, A. De, Giordanengo, V., Partouche, C., Bouchaud, O., Martin, A., Ziol, M., Baazia, Y., Iwaka-Bande, V., Gerber, A., Uzan, M., Bicart-See, A., Garipuy, D., Ferro-Collados, M.J., Virologie, Nicot, F., Gervais, A., Yazdanpanah, Y., Adle-Biassette, H., Alexandre, G., Peytavin, G., Lascoux-Combe, C., Molina, J.M., Bertheau, P., Chaix, M.L., Delaugerre, C., Maylin, S., Lacombe, K., Bottero, J., Krause, J., Girard, P.M., Wendum, D., Cervera, P., Adam, J., Viala, C., Vittecocq, D., Goujard, C., Quertainmont, Y., Teicher, E., Pallier, C., Lortholary, O., Duvivier, C., Rouzaud, C., Lourenco, J., Touam, F., Louisin, C., Avettand-Fenoel, V., Gardiennet, E., Mélard, A., Neau, D., Ochoa, A., Blanchard, E., Castet-Lafarie, S., Cazanave, C., Malvy, D., Dupon, M., Dutronc, H., Dauchy, F., Lacaze-Buzy, L., Desclaux, A., Bioulac-Sage, P., Trimoulet, P., Reigadas, S., Morlat, P., Lacoste, D., Bonnet, F., Bernard, N., Hessamfar, M., J, Paccalin, F., Martell, C., Pertusa, M.C., Vandenhende, M., Mercié, P., Pistone, T., Receveur, M.C., Méchain, M., Duffau, P., Rivoisy, C., Faure, I., Caldato, S., Bellecave, P., Tumiotto, C., Pellegrin, J.L., Viallard, J.F., Lazzaro, E., Greib, C., Zucman, D., Majerholc, C., Brollo, M., Farfour, E., Boué, F., Devoto, J. Polo, Kansau, I., Chambrin, V., Pignon, C., Berroukeche, L., Fior, R., Martinez, V., Abgrall, S., Favier, M., Deback, C., Lévy, Y., Dominguez, S., Lelièvre, J.D., Lascaux, A.S., Melica, G., Billaud, E., Raffi, F., Allavena, C., Reliquet, V., Boutoille, D., Biron, C., Lefebvre, M., Hall, N., Bouchez, S., Rodallec, A., Le Guen, L., Hemon, C., Miailhes, P., Peyramond, D., Chidiac, C., Ader, F., Biron, F., Boibieux, A., Cotte, L., Ferry, T., Perpoint, T., Koffi, J., Zoulim, F., Bailly, F., Lack, P., Maynard, M., Radenne, S., Amiri, M., Valour, F., Augustin-Normand, C., Scholtes, C., Le-Thi, T.T., Piroth, L., Chavanet, P., Duong Van Huyen, M., Buisson, M., Waldner-Combernoux, A., Mahy, S., Salmon Rousseau, A., Martins, C., Aumaître, H., Galim, S., Bani-Sadr, F., Lambert, D., Nguyen, Y., Berger, J.L., Hentzien, M., Brodard, V., Rey, D., Partisani, M., Batard, M.L., Cheneau, C., Priester, M., Bernard-Henry, C., de Mautort, E., Fischer, P., Gantner, P., Fafi-Kremer, S., Roustant, F., Platterier, P., Kmiec, I., Traore, L., Lepuil, S., Parlier, S., Sicart-Payssan, V., Bedel, E., Anriamiandrisoa, S., Pomes, C., Mole, M., Bolliot, C., Catalan, P., Mebarki, M., Adda-Lievin, A., Thilbaut, P., Ousidhoum, Y., Makhoukhi, F.Z., Braik, O., Bayoud, R., Gatey, C., Pietri, M.P., Le Baut, V., Ben Rayana, R., Bornarel, D., Chesnel, C., Beniken, D., Pauchard, M., Akel, S., Lions, C., Ivanova, A., Ritleg, A.-S., Debreux, C., Chalal, L., Zelie, J., Hue, H., Soria, A., Cavellec, M., Breau, S., Joulie, A., Fisher, P., Gohier, S., Croisier-Bertin, D., Ogoudjobi, S., Brochier, C., Thoirain-Galvan, V., Le Cam, M., Wittkop, L., Esterle, L., Izopet, J., Serfaty, L., Paradis, V., Spire, B., Carrieri, P., Zaegel-Faucher, O., Meyer, L., Boufassa, F., Autran, B., Roque, A.M., Solas, C., Fontaine, H., Costagliola, D., Petrov-Sanchez, V., Levier, A., P. Carrieri, Chalouni, M., Conte, V., Dequae-Merchadou, L., Desvallées, M., Gilbert, C., Gillet, S., Guillochon, Q., Khan, C., Knight, R., Marcellin, F., Michel, L., Mora, M., Protopopescu, C., Roux, P., Barré, T., Ramier, C., Sow, A., Di Beo, V., Bureau, M., Marcellin, Fabienne, Brégigeon-Ronot, Sylvie, Ramier, Clémence, Protopopescu, Camelia, Gilbert, Camille, Di Beo, Vincent, Duvivier, Claudine, Bureau-Stoltmann, Morgane, Rosenthal, Eric, Wittkop, Linda, Salmon-Céron, Dominique, Carrieri, Patrizia, Sogni, Philippe, and Barré, Tangui

Published
2023
Full Text
View/download PDF

6. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

Author

Nordmann, S., Vilotitch, A., Roux, P., Esterle, L., Spire, B., Marcellin, F., Salmon‐Ceron, D., Dabis, F., Chas, J., Rey, D., Wittkop, L., Sogni, P., Carrieri, P., Salmon, D, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Valantin, M.A., Pialoux, G, Poizot‐Martin, I, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐See, A, Bouchaud, O, Gervais, A, Lascoux‐Combe, C, Goujard, C, Lacombe, K, Duvivier, C, Vittecoq, D, Neau, D, Morlat, P, Bani‐Sadr, F, Meyer, L, Boufassa, F, Dominguez, S, Autran, B, Roque, A.M., Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Couffin‐Cadiergues, S, Marchand, L, Salmon, D, Alagna, L, Sogni, P, Terris, B, Krivine, A, Katlama, C, Valantin, M.A., Stitou, H, Benhamou, Y, Charlotte, F, Fourati, S, Simon, A, Cacoub, P, Nafissa, S, Poizot‐Martin, I, Zaegel, O, Porcher, M, Tamalet, C, Pialoux, G, Chas, J, Slama, L, Callard, P, Bendjaballah, F, Le Pendeven, C, Marchou, B, Alric, L, Barange, K, Metivier, S, Selves, J, Larroquette, F, Rosenthal, E, Haudebourg, J, Saint‐Paul, M.C., Partouche, C, Bouchaud, O, Ziol, M, Baazia, Y, Uzan, M, Bicart‐See, A, Garipuy, D, Ferro‐Collados, M.J, Selves, J, Nicot, F, Gervais, A, Yazdanpanah, Y, Adle‐Biassette, H, Alexandre, G, Lascoux‐Combe, C, Molina, J.M, Bertheau, P, Duclos, J, Palmer, P, Lacombe, K, Campa, P, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Goujard, C, Pallier, C, Vittecoq, D, Lortholary, O, Duvivier, C, Shoai‐Tehrani, M, Mélard, A, Neau, D, Ochoa, A, Blanchard, E, Castet‐Lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐Buzy, L, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Morlat, P, Lacoste, D, Bonnet, F, Bernard, N, Bonarek Hessamfar, M, Roger‐Schmeltz, J, Gellie, P, Thibaut, P, Paccalin, F, Martell, C, Carmen Pertusa, M, Vandenhende, M, Mercier, P, Malvy, D, Pistone, T, Receveur, M.C, Caldato, S, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Zucman, D, Majerholc, C, Guitard, F, Boué, F, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Billaud, E, Raffi, F, Alavena, C, Rodallec, A, Miailhes, P, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Le‐Thi, T.T, Piroth, L, Chavanet, P, Duong Van Huyen, M, Buisson, M, Waldner‐Combernoux, A, Mahy, S, Binois, R, Simonet‐Lann, A.L, Croisier‐Bertin, D, Aumaître, H, Bani‐Sadr, F, Lambert, D, Nguen, Y, Rouger, C, Berger, J.L, Partrisiani, M, Gautner, P, Batard, M.L, Beniken, D, Lupin, C, Lions, C, Ritleng, A.‐S, Honoré, P, Payssan, V, Breau, S, Joulie, A, Mole, M, Bolliot, C, Touam, F, André, F, Hue, H, Larmet, L, Brochier, C, Thoirain, V, Raho‐Moussa, M, Ogoudjobi, S, Azar, M, Bornarel, D, Gohier, S, Chesnel, C, Maradan, G, Kurkdji, P, Hadjoudj, S, Malet, M, Kmiec, I, Fischer, P, Palacin, A, Pietri, M.P, Le Baut, V, Guet, P, Le Puil, S, Mebarki, M, Fior, A, Adda‐Lievin, A, Conte, V, Delaune, J, Dequae Merchadou, L, Douiri, N, Gillet, S, Gilbert, C, Jacquet, A, Kherraz, R, Lagorse, P, Mora, M, Protopopescu, C, and Rosellini, S

Published
2018
Full Text
View/download PDF

7. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

Author

Fabienne Marcellin, Sylvie Brégigeon-Ronot, Clémence Ramier, Camelia Protopopescu, Camille Gilbert, Vincent Di Beo, Claudine Duvivier, Morgane Bureau-Stoltmann, Eric Rosenthal, Linda Wittkop, Dominique Salmon-Céron, Patrizia Carrieri, Philippe Sogni, Tangui Barré, D. Salmon, R. Usubillaga, P. Sogni, B. Terris, P. Tremeaux, C. Katlama, M.A. Valantin, H. Stitou, A. Simon, P. Cacoub, S. Nafissa, Y. Benhamou, F. Charlotte, Virologie: S. Fourati, I. Poizot-Martin, O. Zaegel, H. Laroche, C. Tamalet, G. Pialoux, J. Chas, P. Callard, F. Bendjaballah, C. Amiel, C. Le Pendeven, B. Marchou, L. Alric, K. Barange, S. Metivier, J. Selves, F. Larroquette, E. Rosenthal, null Infectiologie, A. Naqvi, V. Rio, J. Haudebourg, M.C. Saint-Paul, A. De Monte, V. Giordanengo, C. Partouche, O. Bouchaud, A. Martin, M. Ziol, Y. Baazia, V. Iwaka-Bande, A. Gerber, M. Uzan, A. Bicart-See, D. Garipuy, M.J. Ferro-Collados, null Virologie, F. Nicot, A. Gervais, Y. Yazdanpanah, H. Adle-Biassette, G. Alexandre, G. Peytavin, C. Lascoux-Combe, J.M. Molina, P. Bertheau, M.L. Chaix, C. Delaugerre, S. Maylin, K. Lacombe, J. Bottero, J. Krause, P.M. Girard, D. Wendum, P. Cervera, J. Adam, C. Viala, D. Vittecocq, C. Goujard, Y. Quertainmont, E. Teicher, C. Pallier, O. Lortholary, C. Duvivier, C. Rouzaud, J. Lourenco, F. Touam, C. Louisin, V. Avettand-Fenoel, E. Gardiennet, A. Mélard, D. Neau, A. Ochoa, E. Blanchard, S. Castet-Lafarie, C. Cazanave, D. Malvy, M. Dupon, H. Dutronc, F. Dauchy, L. Lacaze-Buzy, A. Desclaux, P. Bioulac-Sage, P. Trimoulet, S. Reigadas, P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, null J, F. Paccalin, C. Martell, M.C. Pertusa, M. Vandenhende, P. Mercié, T. Pistone, M.C. Receveur, M. Méchain, P. Duffau, C. Rivoisy, I. Faure, S. Caldato, P. Bellecave, C. Tumiotto, J.L. Pellegrin, J.F. Viallard, E. Lazzaro, C. Greib, D. Zucman, C. Majerholc, M. Brollo, E. Farfour, F. Boué, J. Polo Devoto, I. Kansau, V. Chambrin, C. Pignon, L. Berroukeche, R. Fior, V. Martinez, S. Abgrall, M. Favier, C. Deback, Y. Lévy, S. Dominguez, J.D. Lelièvre, A.S. Lascaux, G. Melica, E. Billaud, F. Raffi, C. Allavena, V. Reliquet, D. Boutoille, C. Biron, M. Lefebvre, N. Hall, S. Bouchez, A. Rodallec, L. Le Guen, C. Hemon, P. Miailhes, D. Peyramond, C. Chidiac, F. Ader, F. Biron, A. Boibieux, L. Cotte, T. Ferry, T. Perpoint, J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S. Radenne, M. Amiri, F. Valour, C. Augustin-Normand, C. Scholtes, T.T. Le-Thi, L. Piroth, P. Chavanet, M. Duong Van Huyen, M. Buisson, A. Waldner-Combernoux, S. Mahy, A. Salmon Rousseau, C. Martins, H. Aumaître, S. Galim, F. Bani-Sadr, D. Lambert, Y. Nguyen, J.L. Berger, M. Hentzien, V. Brodard, D. Rey, M. Partisani, M.L. Batard, C. Cheneau, M. Priester, C. Bernard-Henry, E. de Mautort, P. Fischer, P. Gantner, S. Fafi-Kremer, F. Roustant, P. Platterier, I. Kmiec, L. Traore, S. Lepuil, S. Parlier, V. Sicart-Payssan, E. Bedel, S. Anriamiandrisoa, C. Pomes, M. Mole, C. Bolliot, P. Catalan, M. Mebarki, A. Adda-Lievin, P. Thilbaut, Y. Ousidhoum, F.Z. Makhoukhi, O. Braik, R. Bayoud, C. Gatey, M.P. Pietri, V. Le Baut, R. Ben Rayana, D. Bornarel, C. Chesnel, D. Beniken, M. Pauchard, S. Akel, C. Lions, A. Ivanova, A.-S. Ritleg, C. Debreux, L. Chalal, J. Zelie, H. Hue, A. Soria, M. Cavellec, S. Breau, A. Joulie, P. Fisher, S. Gohier, D. Croisier-Bertin, S. Ogoudjobi, C. Brochier, V. Thoirain-Galvan, M. Le Cam, L. Wittkop, L. Esterle, J. Izopet, L. Serfaty, V. Paradis, B. Spire, P. Carrieri, O. Zaegel-Faucher, L. Meyer, F. Boufassa, B. Autran, A.M. Roque, C. Solas, H. Fontaine, D. Costagliola, V. Petrov-Sanchez, A. Levier, null P. Carrieri, M. Chalouni, V. Conte, L. Dequae-Merchadou, M. Desvallées, C. Gilbert, S. Gillet, Q. Guillochon, C. Khan, R. Knight, F. Marcellin, L. Michel, M. Mora, C. Protopopescu, P. Roux, T. Barré, C. Ramier, A. Sow, V. Di Beo, and M. Bureau

Subjects
Hepatology, Gastroenterology, Internal Medicine, Immunology and Allergy
Abstract

A growing literature shows an improvement of chronic hepatitis C virus (HCV)-related depression after successful treatment with direct-acting antivirals. However, depression after HCV cure remains insufficiently documented in people living with HIV (PLWH) and HCV, a population with specific mental health challenges. This study aimed to (i) document the prevalence of moderate-to-severe depression (PHQ-9 score ≥10) across different age classes in HCV-cured PLWH; (ii) identify associated socio-behavioral correlates.Descriptive analyses were performed on data collected during a cross-sectional survey (February 2018 - May 2019) nested in a prospective, multicenter cohort of individuals living with HIV and HCV (ANRS CO13 HEPAVIH). Socio-behavioral correlates of moderate-to-severe depression were identified using logistic regression.Among the 398 HCV-cured individuals in the study sample (median age [IQR]: 56 [53-59] years; 73.1% men), 23.9% presented with moderate-to-severe depression (PHQ-9 score ≥10). Depressive symptom prevalence rates were as follows: anhedonia: 52.3%; feeling 'down' or feelings of hopelessness: 48.3%; sleeping problems: 65.7%; lack of energy: 70.3%; eating disorders: 51.2%; lack of self-esteem: 34.3%; difficulty concentrating: 34.9%; sluggishness (in movement and voice) or restlessness: 24.6%; suicidal ideation: 17.1%. No significant difference was detected across age classes. Female sex, unhealthy alcohol use, sedentary lifestyle, and unhealthy eating behaviors were associated with increased odds of moderate-to-severe depression.Depressive symptoms were common in this sample of HCV-cured PLWH. Unlike findings for the French general population, the prevalence of depression did not decrease with age class. Mental health remains a key issue for HIV-HCV-coinfected individuals, even after HCV cure, especially in women and in individuals with unhealthy behaviors.Despite potential improvements in mental health after successful treatment with direct-acting antivirals, many people living with HIV (PLWH) and hepatitis C virus (HCV) - even in older age classes - still face depressive symptoms after HCV cure. In this population, women and people reporting unhealthy alcohol use, sedentary lifestyle, or unhealthy eating behaviors are more prone to report depressive symptoms after HCV cure. Mental health and lifestyle-related issues should be integrated in a global care model for PLWH living with or having a history of hepatitis C.

Published
2022

8. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

Author

Raffi, François, Le Moing, Vincent, Assuied, Alex, Habak, Sofiane, Spire, Bruno, Cazanave, Charles, Billaud, Eric, Dellamonica, Pierre, Ferry, Tristan, Fagard, Catherine, Leport, Catherine, Leport, C., Raffi, F., Chêne, G., Salamon, R., Moatti, J. P., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Sobel, A., Cuzin, L., Dupon, M., Duval, X., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Hardel, L., Reboud, P., Couffin-Cadiergues, S., Marchand, L., Assuied, A., Carrieri, P., Habak, S., Couturier, F., Jadand, C., Perrier, A., Préau, M., Protopopescu, C., Schmit, J. L., Chennebault, J. M., Faller, J. P., Chirouze, C., Magy-Bertrand, N., Humbert, P., Dupon, M., Longy-Boursier, M., Morlat, P., Neau, D., Granier, P., Ansart, S., Verdon, R., Merrien, D., Chevojon, P., Levy, Y., Sobel, A., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Chidiac, C., Grégoire, V., Reynes, J., May, T., Raffi, F., Fuzibet, J. G., Dellamonica, P., Arsac, P., Bouvet, E., Bricaire, F., Girard, P. M., Herson, S., Leport, C., Monsonego, J., Pialoux, G., Sain, O., Salmon, D., Sellier, P., Roblot, P., Bani-Sadr, F., Michelet, C., Lucht, F., Debord, T., Martin, T., De Jaureguiberry, J. P., Marchou, B., and Bernard, L.

Published
2017
Full Text
View/download PDF

9. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

Author

Couffignal, Camille, Kolta, Sami, Flamant, Martin, Cazanave, Charles, Haymann, Jean-Philippe, Mentre, France, Duval, Xavier, Leport, Catherine, Raffi, Francois, Chêne, G., Salamon, R., Moatti, J., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Cuzin, L., Dupon, M., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Hardel, L., Reboud, P., Couffin-Cadiergues, S., Marchand, L., Assuied, A., Carrieri, P., Habak, S., Couturier, F., Jadand, C., Perrier, A., Préau, M., Protopopescu, C., Schmit, J.L., Chennebault, J.M., Faller, J.P., Magy-Bertrand, N., Chirouze, C., Humbert, P., Neau, D., Granier, P., Ansart, S., Verdon, R., Merrien, D., Chevojon, P., Sobel, A., Levy, Y., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Chidiac, C., Grégoire, V., Reynes, J., Fuzibet, J., Arsac, P., Bouvet, E., Bricaire, F., Monsonego, J., Girard, P.M., Guillevin, L., Herson, S., Molina, J.M., Pialoux, G., Sain, O., Sellier, P., Roblot, F., Bani-Sadr, F., Michelet, C., Lucht, F., Debord, C., Martin, T., de Jaureguiberry, J.P., Bernard, L., Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Physiologie [Bichat-Claude Bernard], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Service des Maladies Infectieuses et Tropicales A [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Hôpital Bichat, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Santé Publique, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Microbiologie Fondamentale et Pathogénicité (MFP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Pharmacie de l'Hôpital Bichat, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Bell Labs (BELL), Lucent Technologies, Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Service de virologie et d'immunologie biologique, Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Unité de Maladies Infectieuses et Tropicales [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service des Maladies Infectieuses et Tropicales [CHU Raymond Poincaré], Hôpital Raymond Poincaré [AP-HP], Centre Hospitalier Libourne, Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Department of Radiation Oncology, Université Catholique de Louvain = Catholic University of Louvain (UCL), GERES - Groupe d'Étude sur le Risque d'Exposition des Soignants aux agents infectieux - Research Group for the Prevention of Occupational Infections in Healthcare Workers [Paris, France], Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Pharmacologie des anti-infectieux (PHAR), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Reims (CHU Reims), University Hospital and University Jean Monnet, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Groupe d'Étude sur le Risque d'Exposition des Soignants aux agents infectieux (GERES), Cholley, Pascal, and Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière]

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, Nevirapine, nevirapine, Immunology, Cumulative Exposure, HIV Infections, 03 medical and health sciences, Absorptiometry, Photon, 0302 clinical medicine, Bone Density, Virology, Internal medicine, medicine, Humans, Prospective Studies, 030212 general & internal medicine, 030304 developmental biology, Bone mineral, 0303 health sciences, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Incidence (epidemiology), HIV, virus diseases, Odds ratio, Middle Aged, medicine.disease, Confidence interval, 3. Good health, Cross-Sectional Studies, Infectious Diseases, Cohort, HIV-1, Coinfection, Reverse Transcriptase Inhibitors, Female, bone mineral density, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies, medicine.drug
Abstract

International audience; We assessed bone mineral density (BMD) in a cohort of human immunodeficiency virus (HIV)-positive patients after a median of 11 years of combination antiretroviral therapy (cART) and evaluated the respective role of HIV infection and antiretroviral drugs (ARVs). A cross-sectional study of 162 participants (131 male) from the ANRS-C08 cohort was performed with bone dual-energy X-ray absorptiometry (DXA) scans and renal assessment. The window of exposure to ARVs was defined as an exposure of more than six cumulative months during the last 3 years before the DXA evaluation to account for a cumulative exposure that could affect bone remodeling. The association with low BMD (Z-score < -2) was assessed by a multiple logistic regression model. The study population was 50 years (median), hepatitis C virus (HCV) (18%), and hepatitis B virus (HBV) (8%) coinfection with HIV-RNA

Published
2020

11. Les auteurs

Author

Isabelle Aubin-Auger, Marie Barais, Jean-Didier Bardet, Marc Bayen, Cyril Bègue, Élise Benedini, Philippe Binder, François Blœdé, Tiphanie Bouchez, Yann Bourgueil, Rémy Boussageon, Jean-Paul Canévet, François Carbonnel, Ludovic Casanova, Juliette Chambe, Benoît Chamboredon, Marc Chanelière, Anthony Chapron, Élodie Charuel, Marine de Chefdebien, Renaud Clément, Pascal Clerc, Guillaume Coindard, Laurence Compagnon, Pauline Cordonnier, David Darmon, Louise Devillers, Clarisse Dibao-Dina, Mathilde Ducloyer, Bérengère Duhoux, Julie Dupouy, Florence Durrieu, Sylvie Erpeldinger, Émile Escourrou, Émilie Ferrat, Laure Fiquet, Luigi Flora, Marie Flori, Mathilde François, Paul Frappé, Anne Freyens, Yoann Gaboreau, Christian Ghasarossian, Julie Gilles de La Londe, Pauline Girard, Xavier Gocko, Dagmar M. Haller, Caroline Huas, Patrick Imbert, Alain Jami, Pauline Jeanmougin, Maeva Jego-Sablier, Jean-Philippe Joseph, Adeline Jouannin, Amar Kapassi, François Kermiche, Shérazade Kinouani, Jérémy Khouani, Marion Lamort-Bouché, Catherine Laporte, Jean-Pierre Lebeau, Julien Le Breton, Laurent Letrilliart, Roxane Liard, Christine Maynié-François, Katia Mazalovic, Alain Mercier, Pierrette Meury Abraham, Stéphanie Mignot, Élodie Million, Eva Mitilian, Yhan Monney, Alain Moreau, Sohela Moussaoui, Sabrina Paradis, Françoise Paumier, Corinne Perdrix, Denis Pouchain, Aline Ramond-Roquin, Cédric Rat, Vincent Renard, Louise Rossignol, Marie-Eve Rougé Bugat, Anne Rousseau, Rosalie Rousseau, Yannick Ruelle, Emeline Salmon, Delphine Sanchez, Matthieu Schuers, Stéphanie Sidorkiewicz, Benoit Tudrej, Juliette Vandendriessche, Cyrille Vartanian, Grégoire Virot, Philippe Vorilhon, Anne Waldner-Combernoux, and Claire Zabawa

Published
2022

13. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity

Author

Bastard, Jean-Philippe, Fellahi, Soraya, Couffignal, Camille, Raffi, François, Gras, Guillaume, Hardel, Lucile, Sobel, Alain, Leport, Catherine, Fardet, Laurence, Capeau, Jacqueline, Leport, C., Raffi, F., Chêne, G., Salamon, R., Moatti, J. P., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Sobel, A., Cuzin, L., Dupon, M., Duval, X., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Reboud, P., Couffin-Cadiergues, S., Marchand, L., Bouteloup, V., Bouhnik, A. D., Brunet-François, C., Caron, V., Carrieri, M. P., Courcoul, M., Couturier, F., Hardel, L., Iordache, L., Kurkdji, P., Martiren, S., Préau, M., Protopopescu, C., Surzyn, J., Taieb, A., Villes, V., Schmit, J. L., Chennebault, J. M., Faller, J. P., Magy-Bertrand, N., Chirouze, C., Humbert, P., Bouchaud, O., Dupon, M., Morlat, P., Ragnaud, J. M., Granier, P., Ansart, S., Verdon, R., Merrien, D., Chevojon, P., Sobel, A., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Peyramond, D., Allard, C., Le Moing, V., May, T., Raffi, F., Fuzibet, J. G., Dellamonica, P., Arsac, P., Bouvet, E., Bricaire, F., Monsonego, J., Girard, P. M., Guillevin, L., Herson, S., Leport, C., Meyohas, M. C., Molina, J. M., Pialoux, G., Sain, O., Salmon, D., Sellier, P., Roblot, F., Jaussaud, R., Michelet, C., Lucht, F., Rapp, C., Chesneau, C., De Jaureguiberry, J. P., Marchou, B., and Bernard, L.

Published
2015
Full Text
View/download PDF

14. Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort

Author

M Chalouni, D Vittecocq, C Rouzaud, C Gilbert, P Bellecave, H Stitou, Thoirain-Galvan, F Touam, C Debreux, D Croisier-Bertin, S Gillet, A de Monte, Patrick Miailhes, F Valour, M L Batard, Lionel Piroth, Joseph Koffi, Y Baazia, Dominique Salmon-Ceron, Morane Cavellec, Gilles Peytavin, B Spire, H Dutronc, C Partouche, Lawrence Serfaty, M Brollo, G Melica, P Catalan, Pascale Trimoulet, P Fischer, David Boutoille, A Mélard, M Mora, P Callard, C Tumiotto, Marianne Maynard, P Bertheau, L Lacaze-Buzy, M Nishimwe, T Pistone, S Fourati, F Roustant, Fabienne Marcellin, Chambrin, S Galim, J Haudebourg, L Traore, S Dominguez, Claudine Duvivier, Brodard, C Rivoisy, M Pauchard, H Laroche, C Katlama, C Allavena, Jean-Daniel Lelièvre, S Fafi-Kremer, K. Barange, S Anriamiandrisoa, D Lacoste, M Desvallees, Karine Lacombe, Marianne Ziol, P Duffau, M Baudoin, Laurent Alric, Y Lévy, Laurent Cotte, Athenaïs Gerber, Rio, P Fisher, C Deback, P Thilbaut, C Louisin, P Platterier, F. Boufassa, Jacques Izopet, S Tezkratt, Reliquet, Philippe Lack, Yazdan Yazdanpanah, Olivier Lortholary, C Pallier, Isabelle Poizot-Martin, S Caldato, Pierre-Marie Girard, A Joulie, P Tremeaux, F Bendjaballah, Julie Chas, François Bailly, J Krause, J Polo Devoto, N Hall, J F Paccalin, Eric Billaud, Yves Benhamou, E Bedel, D. Neau, Tangui Barré, S Gohier, A. Bicart-See, David Zucman, S. Radenne, A S Lascaux, S Ogoudjobi, M L Chaix, C Majerholc, D Malvy, B Marchou, S Reigadas, F Biron, Brigitte Autran, Amaury Martin, C Greib, J Lourenco, Félix Bonnet, E Blanchard, S Bouchez, J Selves, F Dauchy, C Viala, Tristan Ferry, M Partisani, F Marcellin, D. Zucman, D Lambert, Y Ousidhoum, F Z Makhoukhi, P Roux, I Faure, Firouzé Bani-Sadr, Vincent Di Beo, C Le Pendeven, C Protopopescu, M Hentzien, M Le Cam, C Pignon, M Mebarki, A-S Ritleg, M Vandenhende, Hélène Fontaine, Philippe Morlat, C Martins, Marc-Antoine Valantin, Iwaka-Bande, André Boibieux, S Castet-Lafarie, A. Naqvi, Patrice Cacoub, L. Wittkop, A Rodallec, H. Aumaitre, Melina Erica Santos, Dominique Wendum, Petrov-Sanchez, Linda Wittkop, L Berroukeche, I Kansau, D Beniken, Constance Delaugerre, E Farfour, Philippe Sogni, M Buisson, Majid Amiri, François Raffi, David Rey, A Salmon Rousseau, Patrick Mercié, L Le Guen, C Cazanave, Pascal Chavanet, M Santos, Conte, S Akel, P Mercié, E de Mautort, L Chalal, Avettand-Fenoel, Caroline Scholtes, J Zelie, S Nafissa, J F Viallard, D. Lebrasseur-Longuet, Di Beo, Y Nguyen, A Soria, J Adam, C Biron, B Terris, Sarah Maylin, M Favier, Jean-Michel Molina, T Lemboub, Giordanengo, I Kmiec, C. Solas, L Michel, F Charlotte, A.M. Roque, M Hessamfar, C Augustin-Normand, Cécile Goujard, J L Berger, S Breau, H Hue, Sicart-Payssan, J L Pellegrin, P Cervera, A Desclaux, R Bayoud, A. Simon, M Uzan, M Priester, C Cheneau, Caroline Lascoux-Combe, C Chesnel, S Abgrall, M Duong Van Huyen, N Bernard, D Garipuy, E Gardiennet, D Peyramond, D Bornarel, Michel Dupon, F Larroquette, O Zaegel, P Gantner, C Lions, A Waldner-Combernoux, P Miailhes, A Ivanova, Christian Chidiac, Fabien Zoulim, M Mole, R Ben Rayana, H Adle-Biassette, François Nicot, L Esterle, L Meyer, Martinez, F Ader, A Adda-Lievin, P Carrieri, A. Gervais, C Martell, S Mahy, E Lazzaro, P Sogni, T Barré, R Knight, M C Pertusa, J. Bottero, Patrizia Carrieri, T Perpoint, Olivier Bouchaud, D Costagliola, C Gatey, E. Rosenthal, Dominique Salmon, S Lepuil, L Dequae-Merchadou, E Teicher, S Parlier, C Bolliot, G Alexandre, Sophie Metivier, O Braik, M C Receveur, Corinne Brochier, C Hemon, R Usubillaga, François Boué, M Méchain, Camelia Protopopescu, A Ochoa, Catherine Tamalet, M J Ferro-Collados, M P Pietri, P Bioulac-Sage, M C Saint-Paul, T T Le-Thi, M Lefebvre, Paradis, Le Baut, Chloe Pomes, Y Quertainmont, C Bernard-Henry, C Amiel, Gilles Pialoux, R Fior, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Service des maladies infectieuses et tropicales [CH Lyon Sud - HCL] (Hôpital de la Croix-Rousse), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Service Maladies infectieuses et tropicales [AP-HP Hôpital Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Team MORPH3EUS (INSERM U1219 - UB - ISPED), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Interne [Hôpital Foch, Suresnes] (SMI), Hôpital Foch [Suresnes], Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunité Innée - Innate Immunity, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Dupuis, Christine, INSERM U1197, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris]

Subjects
Microbiology (medical), Hepatitis C virus, [SDV]Life Sciences [q-bio], Human immunodeficiency virus (HIV), 030508 substance abuse, HIV Infections, Hepacivirus, medicine.disease_cause, 03 medical and health sciences, Plasma, 0302 clinical medicine, medicine, Humans, In patient, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Cannabis, business.industry, Coinfection, HIV, Cannabis use, Hepatitis C, Chronic, Virology, Antiretroviral therapy, Hepatitis C, 3. Good health, [SDV] Life Sciences [q-bio], Infectious Diseases, Cohort, RNA, 0305 other medical science, business
Abstract

International audience; No abstract available

Published
2020

15. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy

Author

Masquelier, Bernard, Taieb, Audrey, Reigadas, Sandrine, Marchou, Bruno, Cheneau, Christine, Spire, Bruno, Charpentier, Charlotte, Leport, Catherine, Raffi, François, Chêne, Geneviève, Descamps, Diane, Leport, C., Raffi, F., Chêne, G., Salamon, R., Moatti, J.-P., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Sobel, A., Cuzin, L., Dupon, M., Duval, X., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Reboud, P., Couffin-Cadiergues, Sandrine, Marchand, Lucie, Bouteloup, V., Bouhnik, A. D., Brunet-François, C., Caron, V., Carrieri, M. P., Courcoul, M., Couturier, F., Hardel, L., Iordache, L., Kurkdji, P., Martiren, S., Préau, M., Protopopescu, C., Surzyn, J., Taieb, A., Villes, V., Schmit, J. L., Chennebault, J. M., Faller, J. P., Mgy-Bertrand, N., Hoen, B., Drobachef, Bouchaud, O., Dupon, M., Longy-Boursier, Morlat, P., Ragnaud, J. M., Granier, P., Garré, M., Verdon, R., Merrien, D., Devidas, A., Sobel, A., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Peyramond, D., Allard, C., Reynes, J., May, T., Raffi, F., Fuzibet, J. G., Dellamonica, P., Arsac, P., Bouvet, E., Bricaire, F., Bergmann, P., Cabane, J., Monsonego, J., Girard, P. M., Guillevin, L., Herson, S., Leport, C., Meyohas, M. C., Molina, J. M., Pialoux, G., Salmon, D., Roblot, P., Jaussaud, R., Michelet, C., Lucht, F., Debord, T., Rey, D., De Jaureguiberry, J. P., Marchou, B., and Bernard, L.

Published
2011
Full Text
View/download PDF

16. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

Author

Marcellin, Fabienne, primary, Di Beo, Vincent, additional, Aumaitre, Hugues, additional, Mora, Marion, additional, Wittkop, Linda, additional, Duvivier, Claudine, additional, Protopopescu, Camelia, additional, Lacombe, Karine, additional, Esterle, Laure, additional, Berenger, Cyril, additional, Gilbert, Camille, additional, Bouchaud, Olivier, additional, Poizot-Martin, Isabelle, additional, Sogni, Philippe, additional, Salmon-Ceron, Dominique, additional, Carrieri, Patrizia, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaître, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, Lebrasseur-Longuet, D., additional, Usubillaga, R., additional, Terris, B., additional, Tremeaux, P., additional, Katlama, C., additional, Stitou, H., additional, Cacoub, P., additional, Nafissa, S., additional, Benhamou, Y., additional, Charlotte, F., additional, Fourati, S., additional, Zaegel, O., additional, Laroche, H., additional, Tamalet, C., additional, Callard, P., additional, Bendjaballah, F., additional, Amiel, C., additional, Le Pendeven, C., additional, Marchou, B., additional, Alric, L., additional, Metivier, S., additional, Selves, J., additional, Larroquette, F., additional, Rio, V., additional, Haudebourg, J., additional, Saint-Paul, M.C., additional, De Monte, A., additional, Giordanengo, V., additional, Partouche, C., additional, Martin, A., additional, Ziol, M., additional, Baazia, Y., additional, Iwaka-Bande, V., additional, Gerber, A., additional, Uzan, M., additional, Garipuy, D., additional, Ferro-Collados, M.J., additional, Nicot, F., additional, Yazdanpanah, Y., additional, Adle-Biassette, H., additional, Alexandre, G., additional, Molina, J.M., additional, Bertheau, P., additional, Chaix, M.L., additional, Delaugerre, C., additional, Maylin, S., additional, Bottero, J., additional, Krause, J., additional, Girard, P.M., additional, Wendum, D., additional, Cervera, P., additional, Adam, J., additional, Viala, C., additional, Vittecocq, D., additional, Quertainmont, Y., additional, Teicher, E., additional, Pallier, C., additional, Lortholary, O., additional, Rouzaud, C., additional, Lourenco, J., additional, Touam, F., additional, Louisin, C., additional, Avettand-Fenoel, V., additional, Gardiennet, E., additional, Mélard, A., additional, Ochoa, A., additional, Blanchard, E., additional, Castet-Lafarie, S., additional, Cazanave, C., additional, Malvy, D., additional, Dupon, M., additional, Dutronc, H., additional, Dauchy, F., additional, Lacaze-Buzy, L., additional, Desclaux, A., additional, Bioulac-Sage, P., additional, Reigadas, S., additional, Lacoste, D., additional, Bonnet, F., additional, Bernard, N., additional, Hessamfar, J, M., additional, Paccalin, F., additional, Martell, C., additional, Pertusa, M.C., additional, Vandenhende, M., additional, Mercié, P., additional, Pistone, T., additional, Receveur, M.C., additional, Méchain, M., additional, Duau, P., additional, Rivoisy, C., additional, Faure, I., additional, Caldato, S., additional, Bellecave, P., additional, Tumiotto, C., additional, Pellegrin, J.L., additional, Viallard, J.F., additional, Lazzaro, E., additional, Greib, C., additional, Majerholc, C., additional, Brollo, M., additional, Farfour, E., additional, Polo Devoto, J., additional, Kansau, I., additional, Chambrin, V., additional, Pignon, C., additional, Berroukeche, L., additional, Fior, R., additional, Martinez, V., additional, Abgrall, S., additional, Favier, M., additional, Deback, C., additional, Lévy, Y., additional, Dominguez, S., additional, Lelièvre, J.D., additional, Lascaux, A.S., additional, Melica, G., additional, Raffi, F., additional, Allavena, C., additional, Reliquet, V., additional, Boutoille, D., additional, Biron, C., additional, Lefebvre, M., additional, Hall, N., additional, Bouchez, S., additional, Rodallec, A., additional, Le Guen, L., additional, Hemon, C., additional, Peyramond, D., additional, Chidiac, C., additional, Ader, F., additional, Biron, F., additional, Boibieux, A., additional, Cotte, L., additional, Ferry, T., additional, Perpoint, T., additional, Koffi, J., additional, Zoulim, F., additional, Bailly, F., additional, Lack, P., additional, Maynard, M., additional, Radenne, S., additional, Amiri, M., additional, Valour, F., additional, Augustin-Normand, C., additional, Scholtes, C., additional, Le-Thi, T.T., additional, Chavanet, P., additional, Duong Van Huyen, M., additional, Buisson, M., additional, Waldner-Combernoux, A., additional, Mahy, S., additional, Binois, R., additional, Simonet-Lann, A.L., additional, Croisier-Bertin, D., additional, Salmon Rousseau, A., additional, Martins, C., additional, Galim, S., additional, Lambert, D., additional, Nguyen, Y., additional, Berger, J.L., additional, Hentzien, M., additional, Brodard, V., additional, Partisani, M., additional, Batard, M.L., additional, Cheneau, C., additional, Priester, M., additional, Bernard-Henry, C., additional, de Mautort, E., additional, Gantner et S Fafi-Kremer, P., additional, Roustant, F., additional, Platterier, P., additional, Kmiec, I., additional, Traore, L., additional, Lepuil, S., additional, Parlier, S., additional, Sicart-Payssan, V., additional, Bedel, E., additional, Anriamiandrisoa, S., additional, Pomes, C., additional, Mole, M., additional, Bolliot, C., additional, Catalan, P., additional, Mebarki, M., additional, Adda-Lievin, A., additional, Thilbaut, P., additional, Ousidhoum, Y., additional, Makhoukhi, F.Z., additional, Braik, O., additional, Bayoud, R., additional, Gatey, C., additional, Pietri, M.P., additional, Le Baut, V., additional, Ben Rayana, R., additional, Bornarel, D., additional, Chesnel, C., additional, Beniken, D., additional, Pauchard, M., additional, Akel, S., additional, Lions, C., additional, Ivanova, A., additional, Ritleg, A.-S., additional, Debreux, C., additional, Chalal, L., additional, Zelie, J., additional, Hue, H., additional, Soria, A., additional, Cavellec, M., additional, Breau, S., additional, Joulie, A., additional, Fisher, P., additional, Gohier, S., additional, Ogoudjobi, S., additional, Brochier, C., additional, Thoirain-Galvan, V., additional, Le Cam, M., additional, Chalouni, M., additional, Conte, V., additional, Dequae-Merchadou, L., additional, Desvallees, M., additional, Gilbert, C., additional, Gillet, S., additional, Knight, R., additional, Lemboub, T., additional, Marcellin, F., additional, Michel, L., additional, Mora, M., additional, Protopopescu, C., additional, Roux, P., additional, Tezkratt, S., additional, Barré, T., additional, Baudoin, M., additional, Santos, M., additional, Di Beo, V., additional, and Nishimwe, M., additional

Published
2020
Full Text
View/download PDF

20. Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART

Author

Gilles Peytavin, Audrey Taieb, Vincent Le Moing, Bernard Masquelier, Gilles Collin, François Raffi, Catherine Leport, Geneviève Chêne, Anne Waldner-Combernoux, Diane Descamps, Françoise Brun-Vézinet, and Alain Makinson

Subjects
Immunology, HIV Infections, medicine.disease_cause, Virus, Cohort Studies, Proviruses, Antiretroviral Therapy, Highly Active, medicine, Immunology and Allergy, Humans, Protease inhibitor (pharmacology), Mutation, Reverse-transcriptase inhibitor, biology, Nucleotidyltransferase, biology.organism_classification, Virology, Reverse transcriptase, Stop codon, HIV Reverse Transcriptase, CD4 Lymphocyte Count, Infectious Diseases, Treatment Outcome, Lentivirus, DNA, Viral, Codon, Terminator, HIV-1, Reverse Transcriptase Inhibitors, medicine.drug
Abstract

The impact of proviral DNA reverse transcriptase mutations on virological failure was evaluated in 50 HIV-1 HAART-treated patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor. Neither the M184I/V mutation detected in 12 patients nor stop codons at tryptophane positions detected in 13 patients were associated with virological failure. Stop codons appeared under successful therapy in 12 patients. Their presence should be assessed in studies with higher statistical power.

Published
2006

21. An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patients

Author

Anne Waldner-Combernoux, Charlotte Lewden, Jean-Louis Vildé, Jean-Marie Lang, Geneviève Chêne, Catherine Leport, François Bricaire, Hélène Jacqmin-Gadda, Thierry May, and Lise Cuzin

Subjects
Adult, Male, medicine.medical_specialty, HIV Infections, Serology, Cohort Studies, Bias, Internal medicine, Antiretroviral Therapy, Highly Active, Outcome Assessment, Health Care, medicine, Humans, Pharmacology (medical), Prospective Studies, Information bias, Proportional Hazards Models, business.industry, Proportional hazards model, Data Collection, Hazard ratio, virus diseases, Hepatitis C, Hepatitis B, Hepatitis C, Chronic, medicine.disease, Prognosis, digestive system diseases, Confidence interval, Infectious Diseases, Cohort, Immunology, Female, France, business
Abstract

To describe information bias due to missing data for hepatitis C (HCV) status in the analysis of factors associated with mortality in HIV-infected patients.The prospective APROCO cohort enrolled 1,151 HIV-infected adults at the first initiation of highly active antiretroviral treatment in 1997-1998. Conversely to other characteristics, hepatitis B and C serologic status were recorded retrospectively.In a first dataset, HCV status was missing in 29%. HCV infection was associated with a higher hazard of death (Cox model, hazard ratio [HR]=4.1; 95% confidence interval [95% CI], 1.5-11.3). After more efforts to actively document HCV status, the information remained missing in only 10%. All deceased patients who were secondarily documented were recorded as being HCV negative. In fact, before systematic collection of HCV status, nonstructured additional documentation for all deaths led to spontaneous notification of HCV-positive serology at death and not HCV negative. HCV was no longer associated with the hazard of death (HR=1.2; 95% CI, 0.6-2.7).These results underline the need to minimize missing data and to investigate the impact of missing data on the results, although the mechanism of bias is difficult to identify. In addition, these results might shed light on the current debate about the association between HCV and progression of HIV infection.

Published
2004

22. Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients

Author

Catherine Leport, Philippe Clevenbergh, François Raffi, Bruno Marchou, Catherine Rivière, Vincent Le Moing, Marianne Savès, Philippe Morlat, Geneviève Chêne, and Anne Waldner-Combernoux

Subjects
Adult, Male, Hepatitis B virus, Hepatitis C virus, viruses, HIV Infections, Hepacivirus, medicine.disease_cause, Antiviral Agents, Virus, Orthohepadnavirus, Risk Factors, medicine, Humans, Pharmacology (medical), Protease inhibitor (pharmacology), Pharmacology, biology, AIDS-Related Opportunistic Infections, Alanine Transaminase, Hepatitis C, HIV Protease Inhibitors, Hepatitis B, biology.organism_classification, medicine.disease, Virology, Infectious Diseases, Hepadnaviridae, Liver, Immunology, HIV-1, Hepatocytes, Female
Abstract

In a cohort of 1,047 human immunodeficiency virus type 1-infected patients started on protease inhibitors (PIs), the incidence of severe hepatic cytolysis (alanine aminotransferase concentration five times or more above the upper limit of the normal level ≥ 5N) was 5% patient-years after a mean follow-up of 5 months. Only positivity for hepatitis C virus antibodies (hazard ratio [HR], 7.95;P< 10−3) or hepatitis B virus surface antigen (HR, 6.67;P< 10−3) was associated with severe cytolysis. Before starting patients on PIs, assessment of liver enzyme levels and viral coinfections is necessary.

Published
2000

23. Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin

Author

Henri Portier, Anne Waldner-Combernoux, Françoise Ichou, Peter Cornélius Grey, Christine Safran, Jean Paul Kisterman, and Pascal Chavanet

Subjects
Microbiology (medical), Adult, Male, medicine.medical_specialty, Adolescent, medicine.drug_class, Streptococcus pyogenes, Antibiotics, Tonsillitis, Cefpodoxime, Gastroenterology, Drug Administration Schedule, law.invention, Randomized controlled trial, law, Internal medicine, Streptococcal Infections, medicine, Humans, Prodrugs, Child, Antibacterial agent, Aged, Aged, 80 and over, Cefpodoxime Proxetil, General Immunology and Microbiology, business.industry, Ceftizoxime, Pharyngitis, General Medicine, Middle Aged, medicine.disease, Surgery, Regimen, Infectious Diseases, Penicillin V, Female, France, medicine.symptom, business, medicine.drug
Abstract

A total of 220 adults and children > 10 years old (mean 29.5 +/- 11.7 years) with pharyngitis/tonsillitis were randomized to receive either cefpodoxime proxetil 100 mg bid for 5 days (n = 113) or phenoxymethyl penicillin, 600 mg tid for 10 days (n = 107). At the end of treatment of the 166 evaluable patients, a satisfactory clinical response was obtained in 85/88 (96.6%) patients treated with cefpodoxime proxetil and in 75/78 (96.1%) treated with phenoxymethyl penicillin. Group A beta-hemolytic streptococci (GABHS) eradication was similar in both groups: 79/82 (96.3%) patients in the cefpodoxime proxetil group and 64/68 (94.1%) patients in the phenoxymethyl penicillin group. At follow-up (20-30 days after the end of treatment) the GABHS eradication persisted in 67/72 (93.1%) patients treated with cefpodoxime proxetil and in 56/61 (91.8%) patients treated with phenoxymethyl penicillin. Significantly better compliance (p < 0.01) was noticed with the cefpodoxime proxetil regimen compared with the phenoxymethyl penicillin regimen, with only 2/110 (2%) poorly compliant patients in the cefpodoxime proxetil group vs 17/104 (16%) in the phenoxymethyl penicillin group. Thus, the shorter duration of therapy, in conjunction with demonstrated clinical and bacteriological efficacy that is equivalent to standard therapy, makes cefpodoxime proxetil an acceptable alternative for the treatment of GABHS pharyngitis/tonsillitis.

Published
1994

24. Acyclovir pharmacokinetics in plasmapheresis

Author

P Y, Chavanet, F, Bailly, C, Mousson, A, Waldner-Combernoux, F, Lokiec, J M, Rebibou, J M, Chalopin, and H, Portier

Subjects
Adult, Metabolic Clearance Rate, Acyclovir, Humans, Plasmapheresis, Middle Aged, Half-Life
Abstract

During experimental treatment of human immunodeficiency virus (HIV-1) infection using high doses of acyclovir (ACV) (600 mg IV every 8 h), cyclosporin, and several courses of plasmapheresis (PE) (60 ml/kg), ACV pharmacokinetics in three patients have been measured. The results with or without PE were not significantly different: half-time of elimination 3 vs. 2.3 h, volume of distribution 1.8 vs. 1.14 liter/kg, and total clearance 404 vs. 314 ml/min. The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively. These findings suggest that supplemental doses of ACV are not needed when plasmapheresis is performed.

Published
1990

26. Impact of Early versus Late Adherence to Highly Active Antiretroviral Therapy on Immuno-Virological Response: A 3-Year Follow-Up Study

Author

Carrieri, Maria Patrizia, Raffi, François, Lewden, Charlotte, Sobel, Alain, Michelet, Christian, Cailleton, Valérie, Chêne, Geneviève, Leport, Catherine, Moatti, Jean-Paul, Spire, Bruno, Leport, C, Raffi, F, Chêne, G, Salamon, R, Moatti, J-P, Pierret, J, Brun-Vézinet, F, Fleury, H, Peytavin, G, Garraffo, R, Costagliola, D, Dellamonica, P, Katlama, C, Meyer, L, Morin, M, Sicard, D, Sobel, A, Ballereau, F, Bach, M-A, Bourdillon, F, Choutet, P, Delfraissy, J-F, Dormont, J, Souteyrand, Y, Vildé, J-L, Dupon, M, Le Moing, V, Marchou, B, May, T, Morlat, P, Waldner-Combernoux, A, Alfaro, C, Boucherit, S, Cailleton, V, Charlois, C, Droz, C, Duran, S, Ecobichon, JL, Egouy, C, Journot, V, Lassalle, R, Latour, L, Le Moing, V, Lewden, C, Masquelier, B, Nouioua, W, Palmer, G, Petit, C, Préau, M, Roloff, S, Savès, M, Spire, B, and Winum, R

Abstract

Objective To assess the impact of different patterns of adherence to highly active antiretroviral therapy (HAART), in particular, the relative impact of early and late adherence, on long-term immuno-virological response in HIV-infected individuals started on a protease inhibitor-containing regimen.Design Clinical, immuno-virological and self-reported adherence data were collected at 4 (M4), 12 (M12), 20 (M20), 28 (M28) and 36 (M36) months after HAART initiation in the French APROCO cohort.Methods A standardized self-administered questionnaire classified patients as non-adherent, moderately or highly adherent at each visit. Stable viral suppression at both M28 to M36, and a CD4 cell increase >200 between M0 and M36 were used as outcome measures.Results Of the 582 patients followed regularly through M36, 360 patients had complete adherence data. Although 59.2% were highly adherent at M4, only 25.8% maintained consistent high adherence throughout the follow-up. High adherence at M4 was independently associated with both stable viral suppression at M28–M36 [OR (95% CI): 2.8 (1.4–5.5)] and a CD4 cell increase >200 during the same period [OR (95% CI): 3.9 (1.7–9.7)]. However, ‘moderately adherent’ patients between M12 and M36 had the same likelihood [OR (95% CI): 1.9 (1.1–3.2)] as patients who were always high adherent [OR (95% CI): 1.9 (1.1–3.2)] of achieving stable viral load suppression, relative to those who reported non-adherence episodes.Conclusion Optimizing adherence in the early months of treatment is crucial to ensure long-term immuno-virological success. Moderate deviations from high adherence during follow-up have a less negative impact. Priority should be given to interventions aimed to improve adherence in the early months of HAART.

Published
2003
Full Text
View/download PDF

28. Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients

Author

Savès, Marianne, Raffi, François, Clevenbergh, Philippe, Marchou, Bruno, Waldner-Combernoux, Anne, Morlat, Philippe, Le Moing, Vincent, Rivière, Catherine, Chêne, Geneviève, and Leport, Catherine

Abstract

ABSTRACTIn a cohort of 1,047 human immunodeficiency virus type 1-infected patients started on protease inhibitors (PIs), the incidence of severe hepatic cytolysis (alanine aminotransferase concentration five times or more above the upper limit of the normal level ≥ 5N) was 5% patient-years after a mean follow-up of 5 months. Only positivity for hepatitis C virus antibodies (hazard ratio [HR], 7.95;P< 10−3) or hepatitis B virus surface antigen (HR, 6.67; P< 10−3) was associated with severe cytolysis. Before starting patients on PIs, assessment of liver enzyme levels and viral coinfections is necessary.

Published
2000
Full Text
View/download PDF

29. [Meningeal diffusion of cefpirome in adults]

Author

P, Chavanet, A, Pechinot, A, Waldner-Combernoux, A, Kazmierczak, and H, Portier

Subjects
Adult, Male, Meninges, Adolescent, Humans, Female, Meningitis, Middle Aged, Child, Chromatography, High Pressure Liquid, Aged, Cephalosporins
Abstract

Cefpirome is a new aminothiazolyl cephalosporin with a low protein binding, a long half-life of elimination and a wide antibacterial spectrum including pseudomonas and staphylococcus. We studied its diffusion into the cerebrospinal fluid (CSF). Cefpirome, 2 g, was administered intravenously over 3 min. Nineteen patients, aged 12-75 y (mean +/- SD = 40 +/- 20) were studied: 13 had meningitis (septic = 6; chronic = 2; viral = 4). Seric and CSF samples were assayed by the high pressure liquid chromatography (HPLC) procedure. Results at 1, 3, 6, 9 and 12 hours after the infusion were (mean +/- SD) 62.44 +/- 19.8 mg/l, 26.51 +/- 3.7 mg/l, 10.19 +/- 3.3 mg/l, 3.99 +/- 2.3 mg/l, 2 +/- 1.72 mg/l in the serum and 1.1 +/- 1 mg/l, 2.6 +/- 1.8 mg/l, 2.83 +/- 1.7 mg/l, 1.92 +/- 1 mg/l, 1.83 +/- 0.36 mg/l in CSF of bacterial meningitidis respectively. The half-life of elimination were 2.45 h and 9.8 h in the blood and CSF respectively. The area under the curve CSF/serum ratio was 28%. We conclude that cefpirome concentrations in the CSF were above the minimal inhibitory concentrations of almost all the bacteria causing meningitis.

Published
1989

30. [A simplified method of vaccination against rabies after exposure]

Author

Chavanet P, Sureau P, Waldner-Combernoux A, Nordmann P, Beuriat P, Pierre Rollin, and Portier H

Subjects
Immunoenzyme Techniques, Rabies Vaccines, Humans, Serologic Tests, Antibodies, Viral, World Health Organization
Abstract

Vaccination against rabies after exposure to the risk of contamination is currently performed according to the WHO recommendations: 6 injections in 6 visits. We have studied the serological effectiveness of a simplified method using the human diploid-cell rabies vaccine: the vaccine is injected subcutaneously at the rate of 2 doses on day 0, then one dose on day 7 and one dose on day 21. Fifty subjects were vaccinated, and antiglycoprotein antibodies were assayed in serum by the immunoenzymatic technique (EU/ml). Seroconversion with titres above 0.5 EU/ml was observed in all subjects. The antibody titres were 0.127 +/- 1.57, 11.31 +/- 8.87, 10.2 +/- 7.55, and the numbers of subjects with protective titres were 0/50, 11/50, 46/47 and 36/37 on days 0, 7, 21 and 90 respectively. No undesirable side-effect was recorded. The good results obtained with this 2+1+1 vaccination schedule (4 injections in 3 visits) suggest that the recommended method of post-exposure vaccination could be replaced by this simplified method.

Published
1989

31. Altered peripheral nerve conduction in HIV-patients

Author

P Y, Chavanet, M, Giroud, J P, Lancon, J P, Borsotti, A C, Waldner-Combernoux, D, Pillon, E, Maringe, D, Caillot, and H, Portier

Subjects
Adult, Electrophysiology, Male, AIDS-Related Complex, HIV Seropositivity, Neural Conduction, Humans, Female, Peripheral Nerves, Prospective Studies
Abstract

An electrophysiological study on peripheral nerves conduction was performed on HIV-seropositive patients without neurological signs on clinical examination. Eight of the 28 patients (28%) had an infraclinical neuropathy, which was myelinic or axonal and rather distal than proximal. The mechanism of these involvements is not known, but their early existence could justify an early treatment even for asymptomatic patients.

Published
1988

34. GRANULOMATOUS HEPATITIS ASSOCIATED WITH LYME DISEASE

Author

E. Maringe, A. Waldner-Combernoux, J.P. Lancon, Henri Portier, Pascal Chavanet, and D. Pillon

Subjects
medicine.medical_specialty, Lyme disease, business.industry, Granulomatous Hepatitis, Medicine, General Medicine, business, medicine.disease, Dermatology
Published
1987

35. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)

Author

Tangui, Barré, Patrick, Mercié, Caroline, Lions, Patrick, Miailhes, David, Zucman, Hugues, Aumaître, Laure, Esterle, Philippe, Sogni, Patrizia, Carrieri, Dominique, Salmon-Céron, Fabienne, Marcellin, M, Nishimwe, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Fleyriat [Bourg en Bresse], Hôpital Foch [Suresnes], Centre Hospitalier Saint Jean de Perpignan, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Team MORPH3EUS (INSERM U1219 - UB - ISPED), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Agence Nationale de Recherches sur le Sida et les Hépatites Virales, ANRS CO13 HEPAVIH Study Group: D Salmon, L Wittkop, P Sogni, L Esterle, P Trimoulet, J Izopet, L Serfaty, V Paradis, B Spire, P Carrieri, M A Valantin, G Pialoux, J Chas, I Poizot-Martin, K Barange, A Naqvi, E Rosenthal, A Bicart-See, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Neau, P Morlat, F Bani-Sadr, L Meyer, F Boufassa, B Autran, A M Roque, C Solas, H Fontaine, D Costagliola, L Piroth, A Simon, D Zucman, F Boué, P Miailhes, E Billaud, H Aumaître, D Rey, G Peytavin, V Petrov-Sanchez, A Levier, R Usubillaga, B Terris, P Tremeaux, C Katlama, M A Valantin, H Stitou, P Cacoub, S Nafissa, Y Benhamou, F Charlotte, S Fourati, O Zaegel, H Laroche, C Tamalet, P Callard, F Bendjaballah, C Le Pendeven, B Marchou, L Alric, S Metivier, J Selves, F Larroquette, V Rio, J Haudebourg, M C Saint-Paul, A De Monte, V Giordanengo, C Partouche, A Martin, M Ziol, Y Baazia, V Iwaka-Bande, A Gerber, M Uzan, D Garipuy, M J Ferro-Collados, F Nicot, Y Yazdanpanah, H Adle-Biassette, G Alexandre, J M Molina, P Bertheau, M L Chaix, C Delaugerre, S Maylin, J Bottero, J Krause, P M Girard, D Wendum, P Cervera, J Adam, C Viala, D Vittecocq, Y Quertainmont, E Teicher, C Pallier, O Lortholary, C Rouzaud, J Lourenco, F Touam, C Louisin, V Avettand-Fenoel, E Gardiennet, A Mélard, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy, A Desclaux, P Bioulac-Sage, S Reigadas, D Lacoste, F Bonnet, N Bernard, M Hessamfar, J, F Paccalin, C Martell, M C Pertusa, M Vandenhende, P Mercié, T Pistone, M C Receveur, M Méchain, P Duffau, C Rivoisy, I Faure, S Caldato, P Bellecave, C Tumiotto, J L Pellegrin, J F Viallard, E Lazzaro, C Greib, C Majerholc, M Brollo, E Farfour, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez, S Abgrall, M Favier, C Deback, Y Lévy, S Dominguez, J D Lelièvre, A S Lascaux, G Melica, F Raffi, C Allavena, V Reliquet, D Boutoille, C Biron, M Lefebvre, N Hall, S Bouchez, A Rodallec, L Le Guen, C Hemon, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri, F Valour, C Augustin-Normand, C Scholtes, T T Le-Thi, P Chavanet M Duong Van Huyen, M Buisson, A Waldner-Combernoux, S Mahy, A Salmon Rousseau, C Martins, S Galim, D Lambert, Y Nguyen, J L Berger, M Hentzien, V Brodard, M Partisani, M L Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P Fischer, P Gantner, S Fafi-Kremer, F Roustant, P Platterier, I Kmiec, L Traore, S Lepuil, S Parlier, V Sicart-Payssan, E Bedel, S Anriamiandrisoa, C Pomes, M Mole, C Bolliot, P Catalan, M Mebarki, A Adda-Lievin, P Thilbaut, Y Ousidhoum, F Z Makhoukhi, O Braik, R Bayoud, C Gatey, M P Pietri, V Le Baut, R Ben Rayana, D Bornarel, C Chesnel, D Beniken, M Pauchard, S Akel, C Lions, A Ivanova, A-S Ritleg, C Debreux, L Chalal, J Zelie, H Hue, A Soria, M Cavellec, S Breau, A Joulie, P Fisher, S Gohier, D Croisier-Bertin, S Ogoudjobi, C Brochier, V Thoirain-Galvan, M Le Cam, M Chalouni, V Conte, L Dequae-Merchadou, M Desvallees, C Gilbert, S Gillet, R Knight, T Lemboub, F Marcellin, L Michel, M Mora, C Protopopescu, P Roux, S Tezkratt, T Barré, T Rojas Rojas, M Baudoin, M Santos V Di Beo, M Nishimwe, and Admin, Oskar

Subjects
Coinfection, Substance-Related Disorders, Smoking, virus diseases, HIV, HIV Infections, Hepacivirus, HCV cure, Hepatitis C, Chronic, Antiviral Agents, Hepatitis C, digestive system diseases, Marijuana, Sustained virological response, Cross-Sectional Studies, Behavioral changes, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Humans, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Cannabis
Abstract

International audience; BACKGROUND: Thanks to direct-acting antivirals, hepatitis C virus (HCV) infection can be cured, with similar rates in HCV-infected and HIV-HCV co-infected patients. HCV cure is likely to foster behavioral changes in psychoactive substance use, which is highly prevalent in people living with HIV (PLWH). Cannabis is one substance that is very commonly used by PLWH, sometimes for therapeutic purposes. We aimed to identify correlates of cannabis use reduction following HCV cure in HIV-HCV co-infected cannabis users and to characterize persons who reduced their use. METHODS: We used data collected on HCV-cured cannabis users in a cross-sectional survey nested in the ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients, to perform logistic regression, with post-HCV cure cannabis reduction as the outcome, and socio-behavioral characteristics as potential correlates. We also characterized the study sample by comparing post-cure substance use behaviors between those who reduced their cannabis use and those who did not. RESULTS: Among 140 HIV-infected cannabis users, 50 and 5 had reduced and increased their use, respectively, while 85 had not changed their use since HCV cure. Cannabis use reduction was significantly associated with tobacco use reduction, a decrease in fatigue level, paying more attention to one's dietary habits since HCV cure, and pre-HCV cure alcohol abstinence (p = 0.063 for alcohol use reduction). CONCLUSIONS: Among PLWH using cannabis, post-HCV cure cannabis reduction was associated with tobacco use reduction, improved well-being, and adoption of healthy behaviors. The management of addictive behaviors should therefore be encouraged during HCV treatment.

Published
2022

36. HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort)

Author

Perrine Roux, Camelia Protopopescu, Issifou Yaya, Dominique Salmon-Ceron, Lionel Piroth, Eric Rosenthal, Wildo Navegantes de Araújo, Fabienne Marcellin, Melina Erica Santos, Philippe Sogni, Philippe Morlat, Laure Esterle, Maria Patrizia Carrieri, François Bailly, Linda Wittkop, Universidade de Brasilia [Brasília] (UnB), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Sorbonne Paris Cité (USPC), Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’information Médicale [CHU de Bordeaux] (Pôle de Santé Publique), CHU Bordeaux [Bordeaux], Hôpital l'Archet, Laboratoire Motricité Humaine Expertise Sport Santé (LAMHESS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université de Toulon (UTLN)-Université Côte d'Azur (UCA), Service Maladies infectieuses et tropicales [AP-HP Hôpital Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), ANRS CO13 HEPAVIH Study Group: D Salmon, L Wittkop, P Sogni, L Esterle, P Trimoulet, J Izopet, L Serfaty, V Paradis, B Spire, P Carrieri, M A Valantin, G Pialoux, J Chas, I Poizot-Martin, K Barange, A Naqvi, E Rosenthal, A Bicart-See, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Vittecoq, D Neau, P Morlat, F Bani-Sadr, L Meyer, F Boufassa, S Dominguez, B Autran, A M Roque, C Solas, H Fontaine, D Costagliola, L Piroth, A Simon, D Zucman, F Boué, P Miailhes, E Billaud, H Aumaître, D Rey, G Peytavin, V Petrov-Sanchez, A Pailhé, D Salmon, R Usubillaga, P Sogni, B Terris, P Tremeaux, C Katlama, H Stitou, Y Benhamou, F Charlotte, S Fourati, A Simon, P Cacoub, S Nafissa, I Poizot-Martin, O Zaegel, H Laroche, C Tamalet, G Pialoux, J Chas, P Callard, F Bendjaballah, C Le Pendeven, B Marchou, L Alric, S Metivier, J Selves, F Larroquette, E Rosenthal, A Naqvi, V Rio, J Haudebourg, M C Saint-Paul, C Partouche, O Bouchaud, M Ziol, Y Baazia, M Uzan, D Garipuy, M J Ferro-Collados, F Nicot, Y Yazdanpanah, H Adle-Biassette, G Alexandre, C Lascoux-Combe, J M Molina, P Bertheau, M L Chaix, C Delaugerre, S Maylin, J Bottero, J Krause, P M Girard, D Wendum, P Cervera, J Adam, C Viala, C Goujard, Y Quertainmont, E Teicher, C Pallier, D Vittecoq, O Lortholary, C Rouzaud, J Lourenco, F Touam, C Louisin, V Avettand-Fenoel, A Mélard, D Neau, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy, P Bioulac-Sage, S Reigadas, P Morlat, D Lacoste, F Bonnet, N Bernard, M Hessamfar, F Paccalin, C Martell, M C Pertusa, M Vandenhende, P Merciéer, T Pistone, M C Receveur, M Méchain, P Duffau, C Rivoisy, I Faure, S Caldato, J L Pellegrin, J F Viallard, E Lazzaro, C Greib, D Zucman, C Majerholc, E Farfour, F Boué, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez, C Deback, Y Lévy, J D Lelièvre, A S Lascaux, G Melica, E Billaud, F Raffi, C Allavena, V Reliquet, D Boutoille, C Biron, A Rodallec, L Le Guen, P Miailhes, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri, C Scholtes, T T Le-Thi, P Chavanet, M Duong Van Huyen, M Buisson, A Waldner-Combernoux, S Mahy, R Binois, A L Simonet-Lann, D Croisier-Bertin, H Aumaître, F Bani-Sadr, D Lambert, Y Nguyen, J L Berger, D Rey, M Partisani, M L Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P Gantner, S Fafi-Kremer, G Peytavin, F Roustant, I Kmiec, L Traore, S Lepuil, S Parlier, V Sicart-Payssan, E Bedel, C Louisin, M Mole, C Bolliot, M Mebarki, A Adda-Lievin, F Z Makhoukhi, O Braik, R Bayoud, M P Pietri, V Le Baut, D Bornarel, C Chesnel, D Beniken, M Pauchard, S Akel, S Caldato, C Lions, L Chalal, Z Julia, H Hue, A Soria, M Cavellec, S Breau, A Joulie, P Fisher, C Ondo Eyene, S Ogoudjobi, C Brochier, V Thoirain-Galvan, E Boerg, V Conte, L Dequae-Merchadou, M Desvallees, N Douiri, L Esterle, C Gilbert, S Gillet, R Knight, F Marcellin, L Michel, M Mora, C Protopopescu, P Roux, S Tezkratt, I Yaya, T Barré, T Rojas Rojas, V Villes, M Baudoin, M Santos, Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Côte d'Azur (UCA)-Université de Toulon (UTLN)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), and Dupuis, Christine

Subjects
Male, Marijuana Abuse, [SDV]Life Sciences [q-bio], HIV Infections, Hepacivirus, Substance use, medicine.disease_cause, Coffee, MESH: Antiretroviral Therapy, Highly Active, Cohort Studies, MESH: Proportional Hazards Models, MESH: HIV-1, 0302 clinical medicine, Alcohol and weight, Antiretroviral Therapy, Highly Active, MORPH3Eus, MESH: Obesity, MESH: Hepacivirus, 030212 general & internal medicine, MESH: Anti-HIV Agents, MESH: Cohort Studies, MESH: Middle Aged, biology, Coinfection, Confounding, virus diseases, Hepatitis C, MESH: HIV Infections, Middle Aged, 3. Good health, [SDV] Life Sciences [q-bio], Infectious Diseases, Cohort, Female, France, 0305 other medical science, Adult, medicine.medical_specialty, Social Psychology, Anti-HIV Agents, Hepatitis C virus, MESH: Marijuana Abuse, Binge drinking, Marijuana Smoking, 03 medical and health sciences, Thinness, Internal medicine, medicine, Humans, Obesity, Mortality, Proportional Hazards Models, MESH: Hepatitis C, Behavior, 030505 public health, MESH: Thinness, MESH: Humans, business.industry, Public Health, Environmental and Occupational Health, HIV, MESH: Coffee, MESH: Marijuana Smoking, MESH: Adult, biology.organism_classification, medicine.disease, MESH: Male, MESH: Coinfection, MESH: France, HIV-1, Cannabis, business, MESH: Female
Abstract

International audience; Mortality among individuals co-infected with HIV and hepatitis C virus (HCV) is relatively high. We evaluated the association between psychoactive substance use and both HCV and non-HCV mortality in HIV/HCV co-infected patients in France, using Fine and Gray's competing-risk model adjusted for socio-demographic, clinical predictors and confounding factors, while accounting for competing causes of death. Over a 5-year median follow-up period, 77 deaths occurred among 1028 patients. Regular/daily cannabis use, elevated coffee intake, and not currently smoking were independently associated with reduced HCV-mortality (adjusted sub-hazard ratio [95% CI] 0.28 [0.10-0.83], 0.38 [0.15-0.95], and 0.28 [0.10-0.79], respectively). Obesity and severe thinness were associated with increased HCV-mortality (2.44 [1.00-5.93] and 7.25 [2.22-23.6] versus normal weight, respectively). Regular binge drinking was associated with increased non-HCV-mortality (2.19 [1.10-4.37]). Further research is needed to understand the causal mechanisms involved. People living with HIV/HCV co-infection should be referred for tobacco, alcohol and weight control interventions and potential benefits of cannabis-based therapies investigated.

Published
2020

37. Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort)

Author

Dominique Salmon-Ceron, Maria Patrizia Carrieri, Fabienne Marcellin, Linda Wittkop, Marie Costa, Philippe Sogni, Issifou Yaya, Denis Lacoste, Hugues Aumaitre, Jessica Krause, Virginie Villes, Teresa Rojas Rojas, Camelia Protopopescu, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Coordination Régionale de la lutte contre l'infection à VIH (COREVIH Aquitaine), CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin-Hôpital du Tondu, Service des maladies infectieuses [CH Perpignan], Centre Hospitalier Saint Jean de Perpignan, Team MORPH3EUS (INSERM U1219 - UB - ISPED), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’information Médicale [CHU de Bordeaux] (Pôle de Santé Publique), CHU Bordeaux [Bordeaux], Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Descartes - Paris 5 (UPD5), Service Maladies infectieuses et tropicales [AP-HP Hôpital Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiopathologie du système immunitaire (Inserm U1223), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), This work was supported by the French National Agency for Research on Aids and Viral Hepatitis (ANRS: France Recherche Nord & sud Sida-hiv Hépatites), with the participation of Abbott France, Glaxo-Smith-Kline, Roche, Schering-Plough, BMS, Merck-Serono., ANRS CO13 HEPAVIH Study Group : Scientific Committee of the ANRS CO13 HEPAVIH Study Group: D. Salmon (co-Principal investigator), L. Wittkop (co- Principal Investigator), P. Sogni (co-Principal Investigator), L. Esterle (project manager), P. Trimoulet, J. Izopet, L. Serfaty, V. Paradis, B. Spire, P. Carrieri, M.A. Valantin, G. Pialoux, J. Chas, I. Poizot-Martin, K. Barange, A. Naqvi, E. Rosenthal, A. Bicart-See, O. Bouchaud, A. Gervais, C. Lascoux-Combe, C. Goujard, K. Lacombe, C. Duvivier, D. Vittecoq, D. Neau, P. Morlat, F. Bani-Sadr, L. Meyer, F. Boufassa, B. Autran, A.M. Roque, C. Solas, H. Fontaine, D. Costagliola, L. Piroth, A. Simon, D. Zucman, F. Boué, P. Miailhes, E. Billaud, H. Aumaître, D. Rey, G. Peytavin, V. Petrov-Sanchez, A. Pailhé. Clinical Centres (ward/participating physicians): APHP Cochin, Paris (Médecine Interne et Maladies Infectieuses: D. Salmon, R. Usubillaga, Hépato-gastro-entérologie: P. Sogni, Anatomo-pathologie: B. Terris, Virologie: P. Tremeaux), APHP Pitié-Salpétrière, Paris (Maladies Infectieuses et Tropicales: C. Katlama, M.A. Valantin, H. Stitou, Hépato-gastro-entérologie: Y. Benhamou, Anatomo-pathologie: F. Charlotte, Virologie: S. Fourati), APHP Pitié-Salpétrière, Paris (Médecine Interne: A. Simon, P. Cacoub, S. Nafissa), APHM Sainte- Marguerite, Marseille (Service d’Immuno-Hématologie Clinique: I. Poizot-Martin, O. Zaegel, H. Laroche, Virologie: C. Tamalet), APHP Tenon, Paris (Maladies Infectieuses et Tropicales: G. Pialoux, J. Chas, Anatomo-pathologie: P. Callard, F. Bendjaballah, Virologie: C. Le Pendeven), CHU Purpan, Toulouse (Maladies Infectieuses et Tropicales: B. Marchou, Hépato-gastro-entérologie: L. Alric, K. Barange, S. Metivier, Anatomo-pathologie: J. Selves, Virologie: F. Larroquette), CHU Archet, Nice (Médecine Interne: E. Rosenthal, Infectiologie: A. Naqvi, V. Rio, Anatomo-pathologie: J. Haudebourg, M.C. Saint-Paul, Virologie: C. Partouche), APHP Avicenne, Bobigny (Médecine Interne – Unité VIH: O. Bouchaud, Anatomo-pathologie: M. Ziol, Virologie: Y. Baazia), Hôpital Joseph Ducuing, Toulouse (Médecine Interne: M. Uzan, A. Bicart-See, D. Garipuy, M.J. Ferro-Collados, Virologie: F. Nicot), APHP Bichat-Claude Bernard, Paris (Maladies Infectieuses:, A. Gervais, Y. Yazdanpanah, Anatomo-pathologie: H. Adle- Biassette, Virologie: G. Alexandre), APHP Saint-Louis, Paris (Maladies infectieuses: C. Lascoux-Combe, J.M. Molina, Anatomo-pathologie: P. Bertheau, Virologie: M.L. Chaix, C. Delaugerre, S. Maylin), APHP Saint-Antoine (Maladies Infectieuses et Tropicales:, K. Lacombe, J. Bottero, J. Krause P.M. Girard, Anatomo-pathologie: D. Wendum, P. Cervera, J. Adam, Virologie: C. Viala), APHP Bicêtre, Paris (Médecine Interne: C. Goujard, Y. Quertainmont, E. Teicher, Virologie: C. Pallier, Maladies Infectieuses: D. Vittecoq), APHP Necker, Paris (Maladies Infectieuses et Tropicales: O. Lortholary, C. Duvivier, C. Rouzaud, J. Lourenco, F. Touam, C. Louisin: Virologie: V. Avettand-Fenoel, A. Mélard), CHU Pellegrin, Bordeaux (Maladies Infectieuses et Tropicales: D. Neau, A. Ochoa, E. Blanchard, S. Castet-Lafarie, C. Cazanave, D. Malvy, M. Dupon, H. Dutronc, F. Dauchy, L. Lacaze-Buzy, Anatomopathologie: P. Bioulac-Sage, Virologie: P. Trimoulet, S. Reigadas), Hôpital Saint-André, Bordeaux (Médecine Interne et Maladies Infectieuses: Médecine Interne et Maladies Infectieuses: P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, J.F. Paccalin, C. Martell, M.C. Pertusa, M. Vandenhende, P. Merciéer, D. Malvy, T. Pistone, M.C. Receveur, M. Méchain, P. Duffau, C Rivoisy, I. Faure, S. Caldato, Anatomo-pathologie: P. Bioulac-Sage, Hôpital du Haut-Levêque, Bordeaux (Médecine Interne: J.L. Pellegrin, J.F. Viallard, E. Lazzaro, C. Greib, Hôpital FOCH, Suresnes (Médecine Interne: D. Zucman, C. Majerholc, Virologie: E. Farfour), APHP Antoine Béclère, Clamart (Médecine Interne: F. Boué, J. Polo Devoto, I. Kansau, V. Chambrin, C. Pignon, L. Berroukeche, R. Fior, V. Martinez, Virologie: C. Deback), CHU Henri Mondor, Créteil (Immunologie Clinique: Y. Lévy, S. Dominguez, J.D. Lelièvre, A.S. Lascaux, G. Melica), CHU Hôtel Dieu, Nantes (Maladies Infectieuses et Tropicales: E. Billaud, F. Raffi, C. Allavena , V. Reliquet, D. Boutoille, C. Biron, Virologie: A. Rodallec, L. Le Guen), Hôpital de la Croix Rousse, Lyon (Maladies Infectieuses et Tropicales: P. Miailhes, D. Peyramond, C. Chidiac, F. Ader, F. Biron, A. Boibieux, L. Cotte, T. Ferry, T. Perpoint, J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S. Radenne, M. Amiri, Virologie: C. Scholtes, T.T. Le-Thi), CHU Dijon, Dijon (Département d’infectiologie: L. Piroth, P. Chavanet M. Duong Van Huyen, M. Buisson, A. Waldner-Combernoux, S. Mahy, R. Binois, A.L. Simonet-Lann, D. Croisier-Bertin), CH Perpignan, Perpignan (Maladies infectieuses et tropicales: H. Aumaître), CHU Robert Debré, Reims (Médecine interne, maladies infectieuses et immunologie clinique: F. Bani-Sadr, D. Lambert, Y. Nguyen, J.L. Berger), CHRU Strasbourg (Le Trait d’Union: D. Rey, M. Partisani, M.L. Batard, C. Cheneau, M. Priester, C. Bernard- Henry, E. de Mautort, Virologie: P. Gantner et S. Fafi-Kremer), APHP Bichat-Claude Bernard (Pharmacologie: G. Peytavin). Data collection: F. Roustant, I. Kmiec, L. Traore, S. Lepuil, S. Parlier, V. Sicart-Payssan, E. Bedel, F. Touam, C. Louisin, M. Mole, C. Bolliot, M. Mebarki, A. Adda-Lievin, F.Z. Makhoukhi, O. Braik, R. Bayoud, M.P. Pietri, V. Le Baut, D. Bornarel, C. Chesnel, D. Beniken, M. Pauchard, S. Akel, S. Caldato, C. Lions, L. Chalal, Z. Julia, H. Hue, A. Soria, M. Cavellec, S. Breau, A. Joulie, P. Fisher, C. Ondo Eyene, S. Ogoudjobi, C. Brochier, V. Thoirain-Galvan. Management, statistical analyses: E. Boerg, P. Carrieri, V. Conte, L. Dequae- Merchadou,M.Desvallees, N. Douiri, L. Esterle, C. Gilbert, S. Gillet, R. Knight, F. Marcellin, L. Michel, M. Mora, C. Protopopescu, P. Roux, B. Spire, S. Tezkratt, I. Yaya, T. Barré, T. Rojas, V. Villes, M. Baudoin, M. Santos., Dupuis, Christine, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Adult, Male, Sleep Wake Disorders, medicine.medical_specialty, Longitudinal study, Time Factors, Hepatitis C virus, Population, Human immunodeficiency virus (HIV), HIV Infections, Hepacivirus, medicine.disease_cause, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Retrospective Studies, education.field_of_study, Hepatology, Cognitive Behavioral Therapy, business.industry, Gastroenterology, virus diseases, HIV, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Hepatitis C, Chronic, Middle Aged, Sleep in non-human animals, digestive system diseases, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Cohort, Quality of Life, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract

International audience; OBJECTIVES:Although common among patients coinfected with HIV and hepatitis C virus (HCV), sleep disturbances (SD) are still poorly documented in this population in the HCV cure era. This longitudinal study aimed at analysing SD in HIV-HCV coinfected patients and identifying their clinical and sociobehavioural correlates.METHODS:We used 5-year annual follow-up data from 1047 participants in the French National Agency for Research on Aids and Viral Hepatitis Cohort 13 'Hépatite et VIH' (ANRS CO13 HEPAVIH) cohort of HIV-HCV coinfected patients to identify clinical (medical records) and behavioural (self-administered questionnaires) correlates of SD (mixed-effects logistic regression). SD were identified using one item documenting the occurrence of insomnia or difficulty falling asleep (ANRS 'Action Coordonnée 24' self-reported symptoms checklist), and two items documenting perceived sleep quality (Center for Epidemiologic Studies Depression and WHO Quality of Life HIV-specific brief scales).RESULTS:Seven hundred and sixteen (68.4%) patients with completed self-administered questionnaires reported SD at their most recent follow-up visit. In the multivariable model, hazardous alcohol consumption (Alcohol Use Disorders Identification Test-Consumption score≥4 for men, ≥3 for women) (adjusted odds ratio=1.61; 95% confidence interval: 1.09-2.36), depressive symptoms (6.78; 4.36-10.55) and the number of other physical and psychological self-reported symptoms (1.10; 1.07-1.13) were associated independently with SD after adjustment for sex, age and employment status. HCV cure was not associated significantly with SD.CONCLUSION:SD remain frequent in HIV-HCV coinfected patients and are associated with a series of modifiable behavioural risk factors. Independent of HCV cure, improved screening and comprehensive management of alcohol use, physical and psychological self-reported symptoms and depression are essential in this population. Closer investigation of these risk factors of SDs may both increase sleep quality and indirectly improve patients' clinical outcomes.

Published
2019

38. Acyclovir pharmacokinetics in plasmapheresis.

Author

Chavanet PY, Bailly F, Mousson C, Waldner-Combernoux A, Lokiec F, Rebibou JM, Chalopin JM, and Portier H

Subjects
Adult, Half-Life, Humans, Metabolic Clearance Rate, Middle Aged, Acyclovir pharmacokinetics, Plasmapheresis
Abstract

During experimental treatment of human immunodeficiency virus (HIV-1) infection using high doses of acyclovir (ACV) (600 mg IV every 8 h), cyclosporin, and several courses of plasmapheresis (PE) (60 ml/kg), ACV pharmacokinetics in three patients have been measured. The results with or without PE were not significantly different: half-time of elimination 3 vs. 2.3 h, volume of distribution 1.8 vs. 1.14 liter/kg, and total clearance 404 vs. 314 ml/min. The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively. These findings suggest that supplemental doses of ACV are not needed when plasmapheresis is performed.

Published
1990

39. Altered peripheral nerve conduction in HIV-patients.

Author

Chavanet PY, Giroud M, Lancon JP, Borsotti JP, Waldner-Combernoux AC, Pillon D, Maringe E, Caillot D, and Portier H

Subjects
AIDS-Related Complex cerebrospinal fluid, Adult, Electrophysiology, Female, HIV Seropositivity cerebrospinal fluid, Humans, Male, Neural Conduction, Prospective Studies, AIDS-Related Complex physiopathology, HIV Seropositivity physiopathology, Peripheral Nerves physiopathology
Abstract

An electrophysiological study on peripheral nerves conduction was performed on HIV-seropositive patients without neurological signs on clinical examination. Eight of the 28 patients (28%) had an infraclinical neuropathy, which was myelinic or axonal and rather distal than proximal. The mechanism of these involvements is not known, but their early existence could justify an early treatment even for asymptomatic patients.

Published
1988

40. [Meningeal diffusion of cefpirome in adults].

Author

Chavanet P, Pechinot A, Waldner-Combernoux A, Kazmierczak A, and Portier H

Subjects
Adolescent, Adult, Aged, Cephalosporins blood, Cephalosporins cerebrospinal fluid, Child, Chromatography, High Pressure Liquid, Female, Humans, Male, Meningitis blood, Meningitis cerebrospinal fluid, Middle Aged, Cefpirome, Cephalosporins pharmacokinetics, Meninges metabolism, Meningitis metabolism
Abstract

Cefpirome is a new aminothiazolyl cephalosporin with a low protein binding, a long half-life of elimination and a wide antibacterial spectrum including pseudomonas and staphylococcus. We studied its diffusion into the cerebrospinal fluid (CSF). Cefpirome, 2 g, was administered intravenously over 3 min. Nineteen patients, aged 12-75 y (mean +/- SD = 40 +/- 20) were studied: 13 had meningitis (septic = 6; chronic = 2; viral = 4). Seric and CSF samples were assayed by the high pressure liquid chromatography (HPLC) procedure. Results at 1, 3, 6, 9 and 12 hours after the infusion were (mean +/- SD) 62.44 +/- 19.8 mg/l, 26.51 +/- 3.7 mg/l, 10.19 +/- 3.3 mg/l, 3.99 +/- 2.3 mg/l, 2 +/- 1.72 mg/l in the serum and 1.1 +/- 1 mg/l, 2.6 +/- 1.8 mg/l, 2.83 +/- 1.7 mg/l, 1.92 +/- 1 mg/l, 1.83 +/- 0.36 mg/l in CSF of bacterial meningitidis respectively. The half-life of elimination were 2.45 h and 9.8 h in the blood and CSF respectively. The area under the curve CSF/serum ratio was 28%. We conclude that cefpirome concentrations in the CSF were above the minimal inhibitory concentrations of almost all the bacteria causing meningitis.

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results